Vol. 284, Issue 5, H1744-H1750, May 2003
Sodium restriction prevents cardiac hypertrophy and oxidative
stress in angiotensin II hypertension
Caroline
Rugale1,
Sandrine
Delbosc2,
Jean-Paul
Cristol2,
Albert
Mimran1, and
Bernard
Jover1
1 Groupe Rein et Hypertension,
2 Laboratoire de Nutrition et
Athérogénèse, Institut Universitaire de Recherche
Clinique, Université Montpellier I, 34 093 Montpellier,
France
 |
ABSTRACT |
The influence of a low-sodium (LS) diet
was assessed on the cardiac and renal alterations and pro-oxidant
effect associated with a 10-day infusion of angiotensin II (200 or 400 ng · kg
1 · min
1,
osmotic pumps). Tail-cuff pressure (TCP), albuminuria, and renal blood
flow were determined at the end of the experiments. Heart weight index
(HWI) and production of superoxide anion (O
·) by
the left ventricle and H2O2 by the aorta was
measured with the use of bioluminescence. Although the final TCP was
similar in LS and normal sodium (NS) rats infused with high and low
doses of angiotensin II, respectively, the increase in HWI was
prevented by the LS diet. Sodium restriction reduced the rise in
albuminuria without a change in the renal effect of angiotensin II. The
increased production of O
· and
H2O2 observed in NS rats was abrogated in LS
rats. The beneficial influence of dietary sodium restriction on target
organ damage induced by angiotensin II is independent of arterial
pressure reduction and possibly related to attenuation of the
prooxidant effect of the peptide.
heart weight; albuminuria; reactive oxygen species; renal
hemodynamic
 |
INTRODUCTION |
THE DEVELOPMENT OF
cardiac hypertrophy results from the interaction between several
factors, including elevated arterial pressure, angiotensin II (ANG II),
and sodium intake. Although blood pressure is an important determinant
of cardiac mass (8), ANG II may directly increase protein
synthesis and cause myocyte hypertrophy, as reported in cultured
cardiac myocytes isolated from chicks (2) and neonatal
rats (34). In vivo long-term administration of an
initially subpressor dose of ANG II, a model that mimics the
development of human hypertension, induces a gradual rise in blood
pressure associated with a cardiac hypertrophy (7, 14,
17). However, ANG II might increase cardiac mass independently of arterial pressure. This was suggested by the presence of cardiac hypertrophy in rats infused with a nonpressor dose of the peptide (4, 37) or in rats infused with a pressor dose of ANG II and concomitantly treated by hydralazine (7, 37).
The concentration of sodium ion in vitro or dietary sodium intake in
vivo may modulate cardiac mass. In cultured neonatal rat myocardial
myoblasts, cellular protein content and cell size increased when sodium
concentration of the medium was augmented (15). In vivo, a
high-sodium intake increased cardiac mass in normotensive rats
(46) and exacerbated cardiac hypertrophy in hypertensive
rats (12). In humans, sodium intake (assessed by urinary
sodium excretion) and the left ventricular mass index were positively
correlated in hypertensive and normotensive subjects (9).
Conversely, a low-sodium (LS) intake prevents cardiac hypertrophy
associated with two-kidney, one-clip Goldblatt hypertension (5,
26, 32, 36, 41) and ANG II hypertension (27). The
beneficial effect of dietary sodium restriction on cardiac mass may
parallel the change in arterial pressure (5, 41) or can be
independent of arterial pressure reduction (26, 27, 32).
Aside from a direct effect on arterial pressure and cardiac mass, ANG
II and sodium intake may alter the cardiovascular system through an
increased production of reactive oxygen species (19). ANG
II induces an overexpression of cytosolic proteins involved in the
activation of NAD(P)H oxidase of vascular endothelial and smooth muscle
cells (13, 43) and favors the production of reactive
oxygen species, such as superoxide anion (O
·), H2O2, and hydroxyl radical (43).
On the other hand, an important link between sodium intake and
oxidative stress was suggested by the high vascular oxidative activity
of normotensive rats fed a high-salt diet and the reversal by reactive
oxygen species scavengers of altered responsiveness to acetylcholine
associated with high-salt intake (21).
In the present study, we tested the hypothesis that severe and chronic
dietary sodium restriction may reduce the prooxidant effect of ANG II
and prevent the development of cardiac and renal alterations associated
with long-term infusion of the peptide. The dose of ANG II was doubled
in sodium-restricted rats to obtain a level of hypertension similar to
that achieved in sodium-replete rats infused with the low dose of the
peptide. The present results indicate that cardiac hypertrophy,
albuminuria, and hyperproduction of reactive forms of oxygen associated
with ANG II hypertension are prevented by dietary sodium restriction
independently of arterial pressure reductions.
 |
MATERIALS AND METHODS |
The experiments were carried out in 6 groups of 16 Sprague-Dawley rats (Iffa-Credo; L'Arbresle, France) maintained on a
normal sodium (NS) or LS diet. LS rats weighed 200-220 g at the
beginning of studies and NS rats were matched to obtain a similar body
weight before ANG II infusion. The LS diet consisted of a sodium-free rat chow containing <5 mmol sodium/kg and distilled water as drinking fluid. The NS diet was obtained by the addition of 8.7 g NaCl/kg of the food. The sodium content of the diet was modified at least 3 wk
before ANG II infusion to allow the animals to reach a new sodium
balance. Rats were then placed in individual metabolic cages until the
end of experiments. After a 3-day control period, ANG II (Sigma; Paris,
France) was infused subcutaneously via osmotic pumps (model 2002, Alza;
Palo Alto, CA) at the dose of 200 or 400 ng · kg
1 · min
1
for 10 days in rats maintained on the NS and LS diet. Two groups of
rats were infused with distilled water and served as control animals.
Before and during ANG II infusion, body weight, food and water intake,
and urinary excretion of water, sodium, and potassium were measured
daily in all rats. Urinary excretion of albumin and creatinine was
determined before and at the end of treatment period. Tail-cuff
pressure (TCP; Narco Biosystems, Houston, TX) was recorded in conscious
rats before and every second day of the experimental period. On
day 10 of ANG II infusion, groups were split into two
subgroups of eight rats and prepared either for cardiac output and
renal blood flow determination or measurement of tissue production of
reactive forms of oxygen. All procedures were designed in accordance
with French law and institutional guidelines for the care and use of
laboratory animals.
Cardiac output and renal blood flow.
Cardiac output and renal blood flow were evaluated in conscious rats
using 57Co-labeled microspheres (15 ± 1 mm diameter;
New England Nuclear Research Products; Boston, MA). Three hours after
implantation under ether anesthesia, the left ventricular and femoral
arterial catheters were connected to a pressure transducer, and
arterial pressure and heart rate were continuously recorded for 30 min. During the intraventricular injection of microspheres, blood was sampled at the rate of 0.5 ml/min for 2 min for radioactivity counting
and determination of plasma concentrations of sodium, potassium, and
creatinine. At the end of experiments, the heart and the kidneys were
removed and weighed for radioactivity counting. The heart weight index
(HWI) and kidney weight index were calculated as the ratio of the heart
or kidney to body weight (BW, in mg/g) in the 96 rats included in this study.
Detection of reactive oxygen species.
Production of O
· by cardiac tissue and
H2O2 by the thoracic aorta was determined on
freshly isolated tissue. O
· production by the left ventricle was measured after the addition of 250 µM lucigenin, a dose
that does not interfere with measurements (data not shown) and used in
the measurement of O
· production from cardiac
muscle slices (45) and freshly minced ventricles
(11). H2O2 production was
determined on the thoracic aorta as previously described
(6). Briefly, H2O2 production was
assessed with a luminometer (model LKB 1251, Wallac; Turku, Finland)
immediately after addition of phorbol 12-myristate 13-acetate to the
aorta incubated for 30 min with a specific bioluminescence probe
consisting in luminol and horseradish peroxidase.
Analytical methods and statistical analysis.
Plasma and urine concentrations of sodium and potassium were measured
by flame photometry (Corning), and plasma concentration of creatinine
was estimated by the colorimetric method (Beckman). Creatinine
clearance at the end of experiments was calculated. Urinary excretion
of albumin was determined by the immunonephelemetric method
(33).
Results are expressed as means ± SE and were analyzed by
one-factor or two-factor analysis of variance for repeated measures when appropriate. Differences between groups were assessed by the
Bonferroni's test. Within-group differences were evaluated by the
Student's t-test for paired values. Slopes of the linear regression between final TCP and HWI were compared with the use of
Wald's test. A P value of <0.05 was considered
statistically significant.
 |
RESULTS |
Arterial pressure.
As depicted in Fig. 1, TCP was similar
and remained stable throughout studies in the control rats fed either
diet. Infusion of the low dose of ANG II induced a rise in TCP in all
rats; however, the final level of TCP was significantly lower in the LS
than NS rats (157 ± 3 vs. 171 ± 6 mmHg, respectively). When
the high dose of ANG II was given, final TCP was slightly and not
significantly lower in the LS than NS rats (178 ± 4 and 189 ± 10 mmHg, respectively). Interestingly, the final value of TCP was
similar in the LS group infused with the high dose of ANG II and the NS
rats infused with the low dose of ANG II (Fig.
2).

View larger version (16K):
[in this window]
[in a new window]
|
Fig. 1.
Change in tail-cuff pressure (TCP) during angiotensin II
(ANG II; 200 or 400 ng · kg 1 · min 1,
osmotic pumps) infusion in normal-sodium (NS) and low-sodium (LS) rats.
ns, Not significant. * P < 0.05 compared with the
corresponding vehicle-infused group.
|
|

View larger version (18K):
[in this window]
[in a new window]
|
Fig. 2.
Final TCP and heart weight index in ANG II-infused
sodium-replete and sodium-depleted rats. * P < 0.01 compared with the corresponding vehicle-infused group.
|
|
Cardiac mass.
As shown in Fig. 2, HWI was similarly increased by the low and high
dose of ANG II in sodium-replete rats compared with their NS controls
(3.48 ± 0.10 and 3.53 ± 0.11 vs. 2.97 ± 0.04 mg/g BW,
respectively, P < 0.01). In the LS rats, neither the
low nor the high dose of ANG II had a significant effect on HWI
compared with control LS rats (2.72 ± 0.04 and 2.90 ± 0.04 vs. 2.67 ± 0.04 mg/g BW, respectively). Moreover, HWI remained
lower than normotensive NS control rats in hypertensive LS rats. Of
note, HWI was lower in control rats fed the sodium-free diet compared
with the control NS rats (2.67 ± 0.04 vs. 2.97 ± 0.04 mg/g
BW, P < 0.01). In fact, HWI was positively correlated
with the final level of TCP (Fig. 3) and
the slope of the regression line was lower in LS than NS rats
(44.2 ± 1.12 vs. 89.9 ± 1.8 × 10
4
mg · g
1 · mmHg
1,
P < 0.001).

View larger version (20K):
[in this window]
[in a new window]
|
Fig. 3.
Relationship between heart weight index and the final TCP
in rats fed a NS diet or submitted to the severe dietary sodium
restriction.
|
|
Metabolic parameters.
Body weight was similar in all rats before ANG II infusion. Within the
10-day period of observation, body weight gain was lower in LS than NS
rats. The development of ANG II hypertension was associated with a
reduction of body growth in both regimens, the high dose of ANG II
inhibiting weight gain in LS rats (Table 1). As shown in Table 1, food intake was
similar in NS and LS rats infused with the low dose of ANG II or its
vehicle. However, food consumption was reduced in both regimens when
the peptide was given at the high dose.
As shown in Table 1, sodium balance increased in NS rats infused with
the low dose of ANG II. When the dose of ANG II was doubled, sodium
excretion was higher than intake and sodium balance became negative in
NS rats. Water balance was higher in NS rats infused with the low dose
of ANG II, whereas the high dose of ANG II was associated with a
reduction in water balance compared with control NS rats. In the
vehicle-LS rats, sodium balance was slightly negative but the sodium
lost probably corresponds to the residual amount of sodium present in
the LS diet. Infused at the low dose, ANG II induced a weak increase in
urinary sodium excretion. Although it was reduced, body weight gain was
positive, thus suggesting that there was no net loss of body sodium.
When the dose of ANG II was doubled, a significant loss of sodium
accompanied with a body weight arrest was observed in the LS rats. No
significant change in water balance was detected in the LS rats.
The final plasma concentration of sodium was slightly lower and
hematocrit was higher in LS than NS rats infused with ANG II, although
significance was not achieved. Plasma concentration of potassium was
higher in control LS rats compared with control NS rats. ANG II
infusion had no detectable effect on this parameter in either regimen.
Systemic and renal hemodynamics.
At the end of experiments, mean arterial pressure determined in
conscious rats was similarly increased in NS and LS rats infused with
ANG II (Table 2). Cardiac output and
renal blood flow were lower, and total peripheral and renal vascular
resistances were higher in the LS than in NS control rats, although the
level of significance was not achieved. ANG II infusion was associated with a rise in total and renal resistances and with a reduction in
cardiac output and renal blood flow in both sodium regimens. The
systemic and renal effects of ANG II were similar for the two doses
used in the present study.
Plasma concentration of creatinine and creatinine clearance were
comparable in control NS and LS rats. ANG II dose dependently increased
creatinine clearance in the NS rats, whereas infusion of the peptide
was devoid of effect in sodium-depleted rats.
Urinary excretion of albumin.
As depicted in Fig. 4, basal urinary
excretion of albumin was similar in all groups and remained stable
throughout the studies in control NS and LS rats. The marked rise in
albuminuria associated with infusion of the low dose of ANG II in NS
rats was prevented by sodium depletion. When the dose of ANG II was
doubled, albuminuria rose in LS rats, but remained lower than their
corresponding hypertensive NS rats and comparable to that obtained in
the NS rats infused with the low dose of ANG II.

View larger version (14K):
[in this window]
[in a new window]
|
Fig. 4.
Urinary excretion of albumin (UAlbV) determined before
(basal) and at the end (final) of the 10-day period of ANG II infusion
to rats fed the NS or LS diet. * P < 0.05 compared
with the corresponding vehicle group.
|
|
Production of reactive oxygen species.
O
· production by the left ventricle was similar in
the NS and LS control rats (0.24 ± 0.01 and 0.25 ± 0.01 mV/mg tissue, respectively). In the NS rats, O
· production increased by ~50% for the both doses of ANG II. This rise
in O
· production was totally blocked in rats fed
the LS diet. H2O2 production by aorta segments was comparable in the NS and LS control rats (0.59 ± 0.02 and 0.58 ± 0.03 mV/mg tissue). In the NS rats,
H2O2 production increased by 60-70% with
both doses of ANG II. Again, the rise in H2O2
production associated with ANG II infusion was abrogated in rats fed
the LS diet (Fig. 5).

View larger version (17K):
[in this window]
[in a new window]
|
Fig. 5.
Production of superoxide anion (A) by the left
ventricle and H2O2 (B) by the aorta
determined at the end of the 10-day period of ANG II infusion to rats
fed the NS or the LS diet. * P < 0.05 compared with
the corresponding vehicle group.
|
|
 |
DISCUSSION |
In the present study, it was demonstrated that severe dietary
sodium restriction prevented the development of cardiac hypertrophy associated with ANG II, despite the achievement of a similar level of
hypertension obtained by adjusting the dose of the peptide infused. In
addition, the ANG II-induced rise in albuminuria was blunted in
sodium-restricted rats. Interestingly, the increase of reactive oxygen
species production by the heart and aorta in rats infused with ANG II
was also prevented by prior dietary sodium restriction.
Prevention by sodium restriction of the increase in cardiac mass was
accompanied by a slight attenuation of ANG II hypertension compared
with rats fed the regular sodium diet. The reduced responsiveness to
the peptide may be related to a downregulation of ANG II type 1 receptors (1) and/or unopposed vasodilatation mediated by the type 2 receptors, as reported in normotensive rats
(35). Although we cannot exclude the involvement of blood
pressure changes in the prevention of cardiac hypertrophy by sodium
restriction, several reports favor the hypothesis of a
pressure-independent influence of dietary sodium removal on cardiac
mass. In two-kidney, one-clip hypertension, a severe sodium restriction
prevented cardiac growth in the absence of significant antihypertensive
influences (23, 32). In ANG II hypertension, cardiac
hypertrophy was also prevented without a change in blood pressure in
rats submitted to a moderate sodium restriction (27). In
addition, dietary sodium restriction initiated during the established
phase of renovascular hypertension had no effect on blood pressure but
reversed cardiac hypertrophy (36). In the present study,
the dose of ANG II was doubled (400 ng · kg
1 · min
1)
in sodium-depleted rats to achieve a similar level of hypertension in
both sodium regimen groups. In these conditions of similar development
and final level of hypertension and higher ANG II infusion rate, sodium
restriction still precluded the increase in cardiac mass. In addition,
the kidney weight index was similar in all groups, thus suggesting that
the effect of the low sodium intake specifically affected cardiac
growth. Although we cannot exclude its involvement in the cardiac
effect of the LS diet, the lower rate of body growth had probably only
a minor role, if any. With the use of a similar protocol, cardiac
hypertrophy induced by the low dose of ANG II was almost totally
prevented (HWI was 3.16 ± 0.07, n = 12) in rats
fed the LS diet supplemented with a minimal amount of sodium (~700
µmoles per day) that allows normal body weight gain (B. Jover, C. Rugale, and A. Mimran, unpublished observations).
Interestingly, cardiac mass index was also reduced by sodium
restriction in normotensive rats. A comparable finding was previously
reported in sham-operated rats of the two-kidney, one-clip hypertension
(5). In fact, the slope of the linear correlation between
cardiac mass index and arterial pressure was blunted by dietary sodium
restriction as illustrated in Fig. 3. Therefore, sodium intake appears
as an important modulator of cardiac mass independently of the level
and changes of arterial pressure.
Beside changes in pressure overload, the beneficial effect of dietary
sodium restriction on cardiac mass may be related to a reduction of
preload of the heart. In sodium-replete rats, infusion of the low dose
of ANG II was associated with an increase in sodium and water balances.
Interestingly, such changes did not occur in the LS rats, thus
suggesting that prevention of the increase in circulating volume may
participate in the beneficial influence of dietary sodium removal on
cardiac structure. When given at the high dose, ANG II was associated
with a reduction of water balance and achievement of a negative sodium
balance in sodium-replete rats. Such a loss of sodium may represent a
malignant form of hypertension, or, more likely, it may reflect the
activation of the pressure-natriuresis mechanism, which is altered in
ANG II hypertension (38). Despite this sodium wasting
state, cardiac hypertrophy developed in NS rats but not in LS rats, a
finding that does not favor a major role for preload changes in the
antihypertrophic effect of sodium restriction in the present model. In
addition, it was previously reported that severe sodium restriction
prevented the development of cardiac hypertrophy in two-kidney,
one-clip hypertension without change in sodium and water balances
(32).
Together with the increase in arterial pressure and cardiac mass, both
doses of ANG II induced a marked rise in urinary albumin excretion as
well as glomerular filtration rate, equated with creatinine clearance,
in rats fed the NS diet. Previous studies have implicated an increase
in glomerular capillary pressure in the proteinuria associated with ANG
II hypertension (25) and 5/6 nephrectomy
(18). Severe dietary sodium restriction, a maneuver devoid
of effect on hypertension and renal vasoconstriction, prevented both
the proteinuric effect and hyperfiltration associated with infusion of
the low dose of ANG II in the present study. When the dose of ANG II
was doubled, albuminuria rose in rats fed the sodium-free diet without
change in glomerular filtration rate. However, albuminuria was lower in
sodium-depleted than in sodium-replete rats infused with a high dose of
ANG II. These results do not favor a major role of the blunting of
hyperfiltration in the beneficial effect of dietary sodium restriction
on proteinuria. Similar prevention of proteinuria by dietary sodium
restriction was previously described in uninephrectomized spontaneously
hypertensive rats (3) and 5/6 nephrectomy model
(10). In the latter studies (3, 10), it was
clearly shown that reduction in glomerular pressure determined by
micropuncture or arterial pressure did not account for the beneficial
effect of sodium restriction.
The beneficial effects of dietary sodium restriction are probably
multifactorial with complex interactions between various systems such
as the renin-angiotensin-aldosterone system, the sympathetic nervous
system, endothelin, prostaglandins, or the nitric oxide system. Beside
the hormonal systems, the redox status of the cell has been evoked as a
potential mechanism of the cardiovascular alterations associated with
hypertension and/or high-sodium intake. It was demonstrated that
reactive oxygen species are responsible for the functional changes in
the microcirculation of rats fed a high-salt diet (20,
21). In Dahl salt-sensitive rats, it was reported that the
antioxidant capacity was reduced in rats on a normal sodium diet and
worsened when salt intake was increased (22). However, the
influence of a reduced intake of sodium on oxidative stress has not
been investigated. The major goal of the present study was to evaluate
the effect of dietary sodium restriction on the stimulation by ANG II
of the production of reactive oxygen species in the heart and arterial
wall of hypertensive rats. As previously described, ANG II infusion was
associated with a rise in the production of reactive forms of oxygen
(19, 42). A prominent finding of our study is the complete
prevention of the prooxidant effect of the octapeptide in rats fed the
sodium-restricted diet. Particularly, sodium restriction prevented the
hyperproduction of O
· by the left ventricle even
for the high dose of ANG II. Whether the reduction of oxidative stress is a cause or a consequence of the absence of cardiovascular remodeling cannot be unequivocally evoked from the present experiments. A growing
body of evidence points to the free radicals production as one of the
major factors involved in cardiovascular and renal alterations
associated with ANG II hypertension. Treatment with superoxide
dismutase (SOD) reduced spontaneous tone of aorta isolated from rats
infused with ANG II (39) and SOD (19) or SOD
mimetic (29, 30) blunted hypertension induced by ANG II in
rats. Inhibition of the HMG-CoA reductase with various statins was
reported to reduce arterial pressure and to prevent cardiac hypertrophy
and renal injury in models of ANG II-dependent hypertension (31, 45). A link between ANG II-induced generation of oxygen radicals and cellular hypertrophy was demonstrated in aortas of mice genetically deficient in gp91phox (40) and in mouse renal
tubular cells transfected with p22phox antisense
(16), two membrane-bound NADPH oxidase subunit proteins. In addition, ANG II was shown to cause hypertrophy of cultured neonatal
rat cardiac myocytes in part via the generation of reactive oxygen
intermediates (28). Therefore, maneuvers reducing ANG II-stimulated production of reactive oxygen species may prevent end-organ damage associated with ANG II hypertension. Interestingly, ANG II and sodium induced a rise in intracellular pH that triggers cellular growth of cultured vascular smooth muscle cells
(24). In addition, inhibition of the sodium/proton
exchanger decreased O
· generation by human
neutrophil and membrane preparation of NADPH oxidase, thus supporting
the role of the antiporter in the regulation of intracellular pH and NADPH oxidase activity (44). Although many different
mechanisms are probably involved, subtle changes in the activity of the
sodium/proton antiporter may be critical in the beneficial effect of
dietary sodium restriction. The fact that cardiac mass was also reduced in control normotensive sodium-depleted rats without alteration in the
production of free radicals suggests that the cardiac structural changes induced by sodium restriction may be yet independent of modifications in the redox status of the heart. As in normotensive rats, other mechanisms than oxidative stress reduction may have participated in the beneficial effect of dietary sodium restriction on
cardiac hypertrophy in ANG II-hypertensive rats. Further studies are
obviously needed to delineate the relationship between dietary sodium
intake and free radical production, particularly regarding the target
organ damage of arterial hypertension.
 |
ACKNOWLEDGEMENTS |
This work was supported by the Ministère de la Recherche,
Contrat Quadriennal 1999-2002. C. Rugale was the recipient of a scholarship from the Fédération Française de Cardiologie.
 |
FOOTNOTES |
Address for reprint requests and other correspondence: B. Jover, Institut Universitaire de Recherche Clinique, Groupe Rein et
Hypertension, 641 Av du Doyen Gaston Giraud, 34 093 Montpellier Cedex
5, France (E-mail:
jover{at}iurc.montp.inserm.fr).
The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement"
in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
First published December 5, 2002;10.1152/ajpheart.00864.2002
Received 4 October 2002; accepted in final form 26 November 2002.
 |
REFERENCES |
1.
Aguilera, G,
and
Catt K.
Regulation of vascular angiotensin II receptors in the rats during altered sodium intake.
Circ Res
49:
751-758,
1981[Free Full Text].
2.
Baker, KM,
and
Aceto JF.
Angiotensin II stimulation of protein synthesis and cell growth in chick heart cells.
Am J Physiol Heart Circ Physiol
259:
H610-H618,
1990[Abstract/Free Full Text].
3.
Beinstein, JA,
Feiner HD,
Parker M,
and
Dworkin LD.
Superiority of salt restriction over diuretics in reducing renal hypertrophy and injury in uninephrectomized SHR.
Am J Physiol Renal Fluid Electrolyte Physiol
258:
F1675-F1681,
1990[Abstract/Free Full Text].
4.
Crawford, DC,
Chobanian AV,
and
Brecher P.
Angiotensin II induces fibronectin expression associated with cardiac fibrosis in the rat.
Circ Res
74:
727-739,
1994[Abstract/Free Full Text].
5.
De Simone, G,
Devereux RB,
Camargo MJF,
Wallerson DC,
and
Laragh JH.
Influence of sodium intake on in vivo left ventricular anatomy in experimental renovascular hypertension.
Am J Physiol Heart Circ Physiol
264:
H2103-H2110,
1993[Abstract/Free Full Text].
6.
Delbosc, S,
Cristol JP,
Descomps B,
Mimran A,
and
Jover B.
Simvastatin prevents angiotensin II-induced cardiac alterations and oxidative stress.
Hypertension
40:
142-147,
2002[Abstract/Free Full Text].
7.
Dostal, DE,
and
Baker KM.
Angiotensin II stimulation of left ventricular hypertrophy in adult rat heart: mediation by the AT1 receptor.
Am J Hypertens
5:
276-280,
1992[ISI][Medline].
8.
Drayer, J,
Weber MA,
and
De Young DL.
Blood pressure as a determinant of cardiac left ventricular muscle mass.
Arch Intern Med
142:
90-92,
1983.
9.
Du Cailar, G,
Ribstein J,
Daures JP,
and
Mimran A.
Sodium and left ventricular mass in untreated hypertensive and normotensive subjects.
Am J Physiol Heart Circ Physiol
263:
H177-H181,
1992[Abstract/Free Full Text].
10.
Dworkin, LD,
Benstein JA,
Tolbert E,
and
Feiner HD.
Salt restriction inhibits renal growth and stabilizes injury in rats with established renal disease.
J Am Soc Nephrol
7:
437-442,
1996[Abstract].
11.
Ferdinandy, P,
Danial H,
Ambrus I,
Rothery RA,
and
Schulz R.
Peroxynitrite is a major contributor to cytokine-induced myocardial contractile failure.
Circ Res
87:
241-247,
2000[Abstract/Free Full Text].
12.
Frohlich, ED,
Chien Y,
Sesoko S,
and
Pergam BL.
Relationship between dietary sodium intake, hemodynamics, and cardiac mass in SHR and WKY rats.
Am J Physiol Regul Integr Comp Physiol
264:
R30-R34,
1993[Abstract/Free Full Text].
13.
Griendling, KK,
Mineiri CA,
Ollerenshaw JD,
and
Alexander RW.
Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells.
Circ Res
74:
1141-1148,
1994[Abstract/Free Full Text].
14.
Griffin, SA,
Brown WCB,
MacPherson F,
McGrath JC,
Wilson VG,
Korsgaard N,
Mulvany MJ,
and
Lever AF.
Angiotensin II causes vascular hypertrophy in part by a non-pressor mechanism.
Hypertension
17:
626-635,
1991[Abstract/Free Full Text].
15.
Gu, JW,
Anand V,
Shek EW,
Moore MC,
Brady AL,
Kelly WC,
and
Adair TH.
Sodium induces hypertrophy of cultured myocardial myoblasts and vascular smooth muscles cells.
Hypertension
31:
1083-1087,
1998[Abstract/Free Full Text].
16.
Hannken, T,
Schroeder R,
Stahl RAK,
and
Wolf G.
Angiotensin II-mediated expression of p27Kip1 and induction of cellular hypertrophy in renal tubular cells depend on the generation of oxygen radicals.
Kidney Int
54:
1923-1933,
1998[ISI][Medline].
17.
Herizi, A,
Jover B,
Bouriquet N,
and
Mimran A.
Prevention of the cardiovascular and renal effects of angiotensin II by endothelin blockade.
Hypertension
31:
10-14,
1998[Abstract/Free Full Text].
18.
Hostetter, TH,
Olson JL,
Rennke HG,
Venkatachalam MA,
and
Brenner BM.
Hyperfiltration in remnant nephrons: a potentially adverse response to renal ablation.
Am J Physiol Renal Fluid Electrolyte Physiol
241:
F85-F93,
1981[Abstract/Free Full Text].
19.
Laursen, JB,
Rajagopalan S,
Galis Z,
Tarpey M,
Freeman BA,
and
Harrison DG.
Role of superoxide in angiotensin II-induced but not catecholamine-induced hypertension.
Circulation
95:
588-593,
1997[Abstract/Free Full Text].
20.
Lenda, DM,
and
Boegehold MA.
Effect of a high-salt diet on oxidant enzyme activity in skeletal muscle microcirculation.
Am J Physiol Heart Circ Physiol
282:
H395-H402,
2002[Abstract/Free Full Text].
21.
Lenda, DM,
Sauls BA,
and
Boegehold MA.
Reactive oxygen species may contribute to reduced endothelium-dependent dilation in rats fed high salt.
Am J Physiol Heart Circ Physiol
279:
H7-H14,
2000[Abstract/Free Full Text].
22.
Li, S,
Nadar A,
Gregory M,
and
Khan N.
Antioxidant status of the hypertrophic heart of Dahl hypertensive rat as a model for evaluation of antioxidants.
Methods Find Exp Clin Pharmacol
23:
5-12,
2001[ISI][Medline].
23.
Lindpaintner, K,
and
Sen S.
Role of sodium in hypertensive cardiac hypertrophy.
Circ Res
57:
610-617,
1985[Abstract/Free Full Text].
24.
Lyall, F,
Morton JJ,
Lever AF,
and
Cargoe EJ.
Angiotensin II activates Na+/H+ exchange and stimulates growth in cultured vascular smooth muscle cells.
J Hypertension
6, Suppl4:
S438-S441,
1988.
25.
Miller, PL,
Rennke HG,
and
Meyer TW.
Glomerular hypertrophy accelerates hypertensive glomerular injury in rats.
Am J Physiol Renal Fluid Electrolyte Physiol
261:
F459-F465,
1991[Abstract/Free Full Text].
26.
Morgan, T,
Aubert JF,
and
Brunner H.
Interaction between sodium intake, angiotensin II, and blood pressure as a cause of cardiac hypertrophy.
Am J Hypertens
14:
914-920,
2001[ISI][Medline].
27.
Morgan, TO,
Aubert JF,
and
Wang Q.
Sodium, angiotensin II, blood pressure, and cardiac hypertrophy.
Kidney Int
54, Suppl67:
S213-S215,
1998.
28.
Nakamura, K,
Fushimi K,
Kouchi H,
Mihara K,
Miyazaki M,
Ohe T,
and
Namba M.
Inhibitory effects of antioxidants on neonatal rat cardiac myocyte hypertrophy induced by tumor necrosis factor-
and angiotensin II.
Circulation
98:
798-799,
1998.
29.
Nishiyama, A,
Fukui T,
Fujisawa Y,
Rahman M,
Tian RX,
Kimura S,
and
Abe Y.
Systemic and regional hemodynamic response to tempol in angiotensin II-infused hypertensive rats.
Hypertension
37:
77-83,
2001[Abstract/Free Full Text].
30.
Ortiz, MC,
Manriquez MC,
Romero JC,
and
Juncos LA.
Antioxidants block angiotensin II-induced increases in blood pressure and endothelin.
Hypertension
38:
655-659,
2001[Abstract/Free Full Text].
31.
Park, JK,
Müller DN,
Mervaala EMA,
Dechend R,
Fiebeler A,
Schmidt F,
Bieringer M,
Schäfer O,
Lindschau C,
Schneider W,
Ganten D,
Luft FC,
and
Haller H.
Cerivastatin prevents angiotensin II-induced renal injury independent of blood pressure- and cholesterol-lowering effects.
Kidney Int
58:
1420-1430,
2000[ISI][Medline].
32.
Pasquié, JL,
Jover B,
du Cailar G,
and
Mimran A.
Sodium but not chloride ion modulates left ventricular hypertrophy in two-kidney, one clip hypertension.
J Hypertens
12:
1013-1018,
1994[ISI][Medline].
33.
Redon, J,
Baldo E,
Lubre E,
Bertolin V,
Lozano JV,
Miralles A,
and
Pascual JM.
Microalbuminuria, left ventricular mass and ambulatory blood pressure in essential hypertension.
Kidney Int
49, Suppl55:
S81-S84,
1996.
34.
Sadoshima, JI,
and
Izumo S.
Molecular characterization of angiotensin II-induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts. Critical role of the AT1 receptor subtype.
Circ Res
73:
413-423,
1993[Abstract/Free Full Text].
35.
Scheuer, DA,
and
Perrone MH.
Angiotensin type 2 receptors mediate depressor phase of biphasic pressure response to angiotensin II.
Am J Physiol Regul Integr Comp Physiol
264:
R917-R923,
1993[Abstract/Free Full Text].
36.
Sen, S,
and
Young DR.
Role of sodium in modulation of myocardial hypertrophy in renal hypertensive rats.
Hypertension
8:
918-924,
1986[Abstract/Free Full Text].
37.
Susic, D,
Nunez E,
Frohlich ED,
and
Prakash O.
Angiotensin II increases left ventricular mass without affecting myosin isoform mRNAs.
Hypertension
28:
265-268,
1996[Abstract/Free Full Text].
38.
Van Der Mark, J,
and
Kline RL.
Altered pressure natriuresis in chronic angiotensin II hypertension in rats.
Am J Physiol Regul Integr Comp Physiol
266:
R739-R748,
1994[Abstract/Free Full Text].
39.
Wang, HD,
Hope S,
Du Y,
Quinn MT,
Cayatte A,
Pagano PJ,
and
Cohen RA.
Paracrine role of adventitial superoxide anion in mediating spontaneous tone of the isolated rat aorta in angiotensin II-induced hypertension.
Hypertension
33:
1225-1232,
1999[Abstract/Free Full Text].
40.
Wang, HD,
Xu S,
Johns DG,
Du Y,
Quinn MT,
Cayatte AJ,
and
Cohen RA.
Role of NADPH oxidase in the vascular hypertrophic and oxidative stress response to angiotensin II in mice.
Circ Res
88:
947-953,
2001[Abstract/Free Full Text].
41.
Wilczynski, EA,
Yuan B,
and
Leenen FHH
Dietary sodium restriction and the development of two-kidney, one-clip hypertension in young versus adult rats.
Can J Physiol Pharmacol
70:
452-457,
1992[ISI][Medline].
42.
Wilson, SK.
Role of oxygen-derived free radicals in acute angiotensin II-induced hypertensive vascular disease in the rat.
Circ Res
66:
722-734,
1990[Abstract/Free Full Text].
43.
Wolf, G.
Free redical production and angiotensin.
Curr Hypertens Rep
2:
167-173,
2000[Medline].
44.
Wright, J,
Maridonneau-Parini I,
Cragoe EJ, Jr,
Schwartz JH,
and
Tauber AI.
The role of Na+/H+ antiporter in human neutrophil NADPH-oxidase activation.
J Leukoc Biol
43:
183-186,
1988[Abstract].
45.
Xie, YW,
and
Wolin MS.
Role of nitric oxide and its interaction with superoxide in the suppresion of cardiac muscle mitochondrial respiration.
Circulation
94:
2580-2586,
1996[Abstract/Free Full Text].
46.
Yuan, B,
and
Leenen FHH
Dietary sodium intake and left ventricular hypertrophy in normotensive rats.
Am J Physiol Heart Circ Physiol
261:
H1397-H1401,
1991[Abstract/Free Full Text].
Am J Physiol Heart Circ Physiol 284(5):H1744-H1750
0363-6135/03 $5.00
Copyright © 2003 the American Physiological Society